Drug Trial Radar · NCT01303783
Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension
Last checked: Nov 19, 2026Latest source record: Apr 18, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,381
Actual
Start
Apr 2011
Primary completion
May 2012
Study completion May 2012
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Feb 25, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the blood pressure lowering responses of various dose combinations of nifedipine GITS and candesartan as compared to treatment with each component on their own (monotherapy) and placebo (a look-alike tablet without active ingredient). The drugs - nifedipine GITS and candesartan - which are being investigated are currently approved for use in patients with essential hypertension alone or together with other antihypertensive drugs (combination therapy), but the optimal dose of nifedipine GITS and candesartan used together in the treatment of essential hypertension has not been established yet. In this study patients will be treated with various doses of nifedipine GITS and/or candesartan or placebo. These different regimens will be administered once a day and will be assessed based on their blood pressure lowering effects (mean sitting diastolic blood pressure) in subjects with mild to moderate essential hypertension.
Conditions
- Hypertension, Essential
Interventions
Candesartan cilexetil (Atacand), 4 mgDrug
4 mg of candesartan as capsule
Candesartan cilexetil (Atacand), 8 mgDrug
8 mg candesartan as capsule
Nifedipine GITS (Adalat, BAYA1040), 20 mgDrug
20 mg nifedipine as tablet
Nifedipine GITS (Adalat, BAYA1040), 30 mgDrug
30 mg nifedipine as tablet
Nifedipine GITS (Adalat, BAYA1040), 60 mgDrug
60 mg nifedipine as tablet
PlaceboDrug
3 different placebo tablets corresponding nifedipine doses and 1 placebo capsule corresponding to candesartan doses
Candesartan cilexetil (Atacand), 16 mgDrug
16 mg of candesartan as capsule
Candesartan cilexetil (Atacand), 32 mgDrug
32 mg of candesartan as capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary efficacy variable is the change from baseline in mean seated diastolic blood pressure (MSDBP) at Week 8Time frame: Baseline taken at Visit 1; primary outcome variable assesed at 8 weeks
Locations
157 sites in 13 countries. Site status is shown where the registry gives one.
Site not named
Mobile, Alabama
Site not named
Los Angeles, California
Site not named
Coral Gables, Florida
Site not named
Deerfield Beach, Florida
Site not named
Deerfield Beach, Florida
Site not named
Fort Lauderdale, Florida
Site not named
Jacksonville, Florida
Site not named
West Palm Beach, Florida
Site not named
Atlanta, Georgia
Site not named
Valparaiso, Indiana
Site not named
Charlotte, North Carolina
Site not named
Harrisburg, North Carolina
Site not named
Raleigh, North Carolina
Site not named
Salisbury, North Carolina
Site not named
Cincinnati, Ohio
Site not named
Philadelphia, Pennsylvania
Site not named
Greenville, South Carolina
Site not named
Mt. Pleasant, South Carolina
Site not named
Dallas, Texas
Site not named
San Antonio, Texas
Site not named
Salt Lake City, Utah
Site not named
Salt Lake City, Utah
Site not named
Kenosha, Wisconsin
Site not named
Bahía Blanca, Buenos Aires, Argentina
Site not named
Quilmes, Buenos Aires, Argentina
Site not named
Zárate, Buenos Aires, Argentina
Site not named
Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Site not named
Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Site not named
Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Site not named
Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Site not named
Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Site not named
Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Site not named
Córdoba, Córdoba Province, Argentina
Site not named
Córdoba, Córdoba Province, Argentina
Site not named
Corrientes, Corrientes Province, Argentina
Site not named
Rosario, Santa Fe Province, Argentina
Site not named
Santa Fe, Santa Fe Province, Argentina
Site not named
De Pinte, Belgium
Site not named
Deurne, Belgium
Site not named
Ham, Belgium
Showing 40 of 157 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.